We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess
News

Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess

Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess
News

Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cobra Biologics and Tecrea have been awarded a 15 month collaborative grant of £112,291 ($166,000 USD) by the UK’s innovation agency, Innovate UK for the development of a scalable Adeno Associated Virus (AAV) production bioprocess. 

The grant is awarded under Innovate UK’s ‘Technology Inspired Innovation’ competition, which aims to stimulate innovation within biosciences, identified by UK government as one of four key enabling technology areas.  

The collaboration between Cobra Biologics and Tecrea focuses on the development of a robust, large scale bioprocess for AAV production. AAV is a safe and effective gene therapy vector with a growing commercial demand that cannot be met by current, non-scalable production approaches. The new system aims to achieve scalable GMP production of AAV at low cost by combining NanoCargo™, an efficient, low toxicity nanoparticle-based transfection system from Tecrea with Cobra’s small footprint hollow fibre bioreactors and manufacturing expertise. 

Dr Daniel Smith, CSO Cobra Biologics, commented: “We are looking forward to collaborating closely with Tecrea, and their innovative delivery system. This is a very exciting project for Cobra, as it has the potential to expand our current viral production offering for AAV, providing a scalable route for viral vector production using a transient transfection approach.”

Dr John Ridden, Director at Tecrea, said: “We are delighted to be working with Cobra Biologics on this project. This grant is a great opportunity for us to move our exciting nanotechnology delivery platform into large-scale transfection, which in turn could result in significant improvements in the production of new therapies.”

Advertisement